Human C-C Chemokine Receptor Type 3 (CCR3) Protein

Product specifications

Proteins and Peptides

C-C Chemokine Receptor Type 3 (CCR3)

E. coli

Human

Unconjugated

Concentration: Prior to lyophilization: 200 µg/ml
Sequence Fragment: Please enquire.
Tag: N-terminal His tag

Recombinant

> 90%

1 mg

5 mg

Lyophilized To keep the original salt concentration, we recommend reconstituting to the original concentration prior to lyophilization (see Concentration) in ddH2O. If a lower concentration is required, dilute in PBS, pH 7.4. If a higher concentration is required, the product can be reconstituted directly in PBS, pH 7.4, though please note that this will change the overall salt concentration. The stock concentration should be between 0.1-1.0 mg/ml. Do not vortex.

WB, SDS-PAGE

Prior to lyophilization: PBS, pH 7.4, containing 0.01% Sarcosyl, 1 mM DTT, 5% Trehalose and Proclin-300.

Shipped within 1-2 months.

Store at 2-8 °C for up to one month. Store at -80 °C for up to one year. Avoid repeated freeze/thaw cycles.

No

CCR3,C C CKR3,CC-CKR-3,CD193,CKR 3,CKR3,CMKBR3,Chemokine (C-C motif) receptor 3

Protein CCR3

RUO

This product is for research use only.   Not for human consumption, cosmetic, therapeutic or diagnostic use.

Descripción

C-C Chemokine Receptor Type 3 (CCR3) is a G-protein-coupled receptor (GPCR) that binds multiple chemokines, including CCL11 (eotaxin), CCL24 (eotaxin-2), and CCL5 (RANTES). CCR3 is predominantly expressed on eosinophils, basophils, mast cells, and Th2 lymphocytes, making it a critical regulator of allergic inflammation and immune responses. CCR3 signaling promotes eosinophil chemotaxis, activation, and survival, leading to the accumulation of eosinophils at sites of allergic inflammation, such as in asthma, allergic rhinitis, and atopic dermatitis. Additionally, CCR3 expression on retinal pigment epithelial cells and microglia links it to age-related macular degeneration (AMD) and other neuroinflammatory conditions. In parasitic infections, CCR3 plays a protective role by guiding eosinophils to sites of helminth invasion, contributing to parasite clearance. However, excessive CCR3 activation in chronic inflammation can exacerbate tissue damage and fibrosis. CCR3 is also expressed in certain cancers and may promote angiogenesis and tumor progression by recruiting pro-inflammatory cells to the tumor microenvironment. As a key mediator of allergic and inflammatory diseases, CCR3 is a promising target for therapeutic intervention. CCR3 antagonists and neutralizing antibodies are being explored for treating eosinophilic disorders, asthma, and ocular diseases, where inhibition of CCR3 can reduce eosinophil recruitment, inflammation, and tissue damage. Ongoing research into CCR3 biology continues to uncover its broader implications in inflammation, immunity, and cancer.

Related Products

APC Anti-Human CD56 (B-A19)

Ver Producto

APC Anti-Human CD193(5E8)

Ver Producto

Human CCR3 (C-C chemokine receptor type 3) ELISA Kit

Ver Producto